RA Capital leads Series A round for Curevo Vaccine

Curevo Vaccine, a clinical-stage biotechnology company, has raised $60 million in Series A financing.

10 February 2022•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles